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ABSTRACT | Chemotherapy often targets dividing cells by causing DNA damage 
that leads to replication-dependent toxic lesions. Cells possess several 
overlapping DNA damage repair pathways that allow them to survive these 
treatments. Inhibitors of DNA repair are therefore used in combination therapy to 
modulate the efficacy of DNA damaging drugs. Since DNA repair pathways are 
commonly altered during tumour development, cancer cells will depend on a 
remaining subset of DNA repair pathways for survival. These remaining 
pathways can be targeted by DNA repair inhibitors as monotherapy to selectively 
kill cancer cells. The advantage of DNA repair inhibition as a single agent therapy 
is that it selectively increases unrepaired endogenous DNA damage in tumour 
cells and therefore appears to have fewer side effects in non-cancerous cells. 
DNA damage response and repair inhibitors may also be used to amplify 
oncogene- or hypoxia-induced replication stress and convert these lesions into 
fatal replication lesions.  
 
 
 
At a glance 
 
• Several anti-cancer chemotherapy drugs work by causing excessive DNA damage 
that is converted into toxic lesions during DNA replication. Survival is promoted 
through repair of these lesions by a number of DNA repair pathways that have 
overlapping substrate specificities. The efficacy of anti-cancer drugs is therefore 
highly influenced by cellular DNA repair capacity. Inhibitors of DNA repair 
increase the efficacy of DNA damaging anti-cancer drugs in preclinical models. 
Small molecule inhibitors of DNA repair have been combined with conventional 
chemotherapy drugs in several phase I-II clinical trials.  
 
• Tumour development is commonly associated with perturbed DNA damage 
response and repair pathways. This result in reduced DNA repair capacity and 
increased genetic instability of tumour cells. DNA repair pathways have 
overlapping specificities and defects in one pathway can be compensated for by 
other pathways. These compensating pathways can be identified in synthetic 
lethal screens and then specifically targeted for treatment of DNA repair-defective 
tumours.  
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• Inhibitors of DNA repair can work as single agents for targeted treatment of DNA 
repair-defective cancers. This hypothesis is currently being tested in phase II trials 
where patients with breast or ovarian cancers defective in homologous 
recombination are treated with a PARP inhibitor to target an overlapping 
pathway, DNA single-strand break repair (SSBR). 
 
• Tumours often exhibit replication stress as a consequence of oncogene-induced 
growth signals or hypoxia-induced replication arrest. DNA repair inhibitors could 
be used to prevent the repair of replication lesions present in tumour cells and 
convert them into fatal replication lesions that specifically kill cancer cells. 
 
 
 
 
 
Cancer therapy usually involves exposing the body to cytotoxic agents, administered with 
the aim of killing malignant cells more efficiently than normal tissue. The therapy must 
therefore exploit specific molecular and cellular features of the cancer it is aiming to 
eliminate. One fundamental characteristic of cancer cells is that they are rapidly 
proliferating and therefore most anti-cancer drugs target the cell cycle in various ways. 
Cell division can be targeted directly by inhibitors of the mitotic spindle, thus preventing 
equal division of DNA to the two daughter cells. The growth signals that result in entry 
into the cell cycle can be targeted by hormonal manipulation, therapeutic antibodies and 
drugs that inhibit growth signalling pathways. However, the most common means of 
targeting the cell cycle is to exploit the impact of DNA damaging drugs on DNA 
replication during S phase. When cells attempt to replicate the damaged DNA more 
severe lesions are generated, thus making DNA damaging treatments more toxic to 
replicating cells than non-replicating cells. The toxicity of DNA damaging drugs can 
however be reduced by the activities of several overlapping DNA repair pathways which 
remove lesions before the onset of DNA replication. DNA repair pathways thus modulate 
the efficacy of cancer therapy. In addition, they are frequently mutated in cancers. These 
two features make DNA repair a promising target for novel cancer treatments.   
 
DNA damaging agents in cancer treatment 
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Many anti-cancer drugs employed in the clinic have been used for several decades and 
are highly efficient in killing proliferating cells by interfering with DNA replication 
through a range of different mechanisms (Figure 1). The principal mechanism by which 
toxicity is achieved is by obstruction of replication fork progression, which can lead to 
replication fork collapse, resulting in the formation of replication-associated DNA 
double-strand breaks (DSBs). DSBs are generally considered to be the main toxic DNA 
lesions that kill cells by induction of apoptosis 1,2.  
Common types of DNA damage that interfere with replication fork progression are 
chemical modifications (adducts) of DNA bases, caused by reactive drugs that covalently 
bind DNA, either directly or after being metabolised in the body. These alkylating agents 
are grouped in two categories; mono-functional alkylating agents with one active moiety 
that modifies single bases, while bi-functional alkylating agents have two reactive sites 
and crosslink two bases within the same DNA strand (intra-strand crosslinks) or between 
opposite DNA strands (inter-strand crosslinks). Such inter-strand crosslinks pose a 
complete block to replication forks. 
The DNA synthesis process itself is often targeted by chemotherapy, either 
through the use of replication inhibitors or by anti-metabolites. DNA replication 
inhibitors such as aphidicolin directly inhibit DNA polymerases 3, whereas the radical 
scavenger hydroxyurea inhibits ribonucleotide reductase, required for production of 
deoxyribonucleotides (dNTPs) that are used for DNA synthesis 4.  Replication inhibitors 
can be regarded as DNA damaging agents because, as explained above, impaired 
replication fork progression causes DNA lesions including DSBs 5,6. Anti-metabolites 
resemble nucleotides or nucleotide precursors and act by inhibiting nucleotide 
metabolism pathways, thus depleting cells of dNTPs. They can also impair replication 
fork progression by becoming incorporated into the DNA 7. In general, the biochemical 
mechanisms of cell death induced by anti-metabolites are poorly understood.  
Another means of interfering with replication is to exploit DNA strand breaks that 
arise naturally during the process of DNA synthesis. Topoisomerases are a group of 
enzymes which resolve torsional strains imposed on the double helix during DNA 
replication. They induce transient DNA breaks to relax supercoiled DNA or allow DNA 
strands to pass through each other 8. Topoisomerase inhibition, a common strategy for 
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anticancer treatment, prevents re-sealing of these breaks causing replication-associated 
DSBs 1,2.  
 Ionizing radiation and “radiomimetic” agents such as bleomycin cause 
replication-independent DSBs that efficiently kill non-replicating cells. However, 
radiation rapidly prevents replication by activation of cell cycle checkpoints to avoid 
formation of toxic DNA replication lesions 9. These cell cycle checkpoints are regulated 
by effector kinases, such as ATM and ATR 10-12 which regulate the activities of 
downstream checkpoint proteins such as Chk1 and Chk2. . Defects in DNA damage 
checkpoint pathways result in sensitivity to a range of anti-cancer treatments, (e.g. loss of 
ATM results in sensitivity to ionizing radiation 13) and inhibitors of these checkpoint 
pathways are being explored in the treatment of cancer, as discussed below.  
 
Chemotherapy-induced DNA lesions are efficiently repaired  
DNA repair activity largely determines the efficacy of anti-cancer drugs in causing 
tumour regression. Direct DSBs are mainly repaired by non-homologous end joining 
(NHEJ)14, whereas replication-associated DSBs are repaired by homologous 
recombination (HR)15 and related replication repair pathways, as discussed below. DNA 
adducts, such as those created by alkylating agents, may be excised and repaired before 
they are confronted by the replication machinery. This is achieved by base excision 
repair (BER), excising a single damaged DNA base or a short strand containing the 
damaged base 16 or nucleotide excision repair (NER), which excises a single-stranded 
DNA molecule of approximately 24 to 30 base pairs containing the DNA lesion 17,18. 
Damaged DNA can also be repaired without removal of the damaged base, in a process 
that directly reverses the DNA alkylation 19. The O6-methylguanine methyl transferase 
(MGMT) is an alkyltransferase and removes alkylations on the O6 position of guanine 
produced from the anti-cancer drugs such as temozolomide 20, and the DNA-dioxygenases 
ABH2 and ABH3 revert 1-methyladenine and 3-methylcytosine back to adenine or 
cytosine respectively21. The repair of alkylated lesions is thought to be quick, with the 
majority of lesions appearing to be repaired within one hour 22. If the lesions are removed 
before initiation of replication, the efficiency of alkylating agents in killing the tumour is 
significantly reduced. Thus, modulation of DNA repair clearly influences the efficacy of 
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alkylating agents, and resistance to alkylating agents is often explained by upregulation 
of DNA repair proteins. 
Whereas most DNA repair pathways mediate resistance to DNA damage, 
mismatch repair (MMR) is actually required for the toxicity of several anti-cancer drugs 
(Figure 1). This has been explained by the “futile repair cycle” model in which mismatch 
repair removes the newly inserted intact base instead of the damaged base, triggering 
subsequent rounds of futile repair which might be deleterious 23. It is also possible that 
mismatch repair might have an important role in triggering checkpoint signalling and 
apoptosis, which might mediate increased toxicity 24. It has been established that a defect 
in mismatch repair is associated with resistance to many DNA damaging anti-cancer 
agents, such as mono- and bi-functional alkylators and antimetabolites 7,23,25. It should be 
noted that mismatch repair acts directly at replication forks and can therefore not prevent 
them from encountering damage. 
Collapse of replication forks during DNA synthesis can be avoided by bypassing 
DNA lesions in a process called translesion synthesis 26,27. This process is carried out by 
switching the regular polymerases epsilon and delta, responsible for leading and lagging 
strand synthesis respectively 28,29, to polymerases with different substrate specificities, 
thus enabling them to bypass different types of damaged bases 30. 
Once replication forks stall or collapse upon encountering DNA damage other 
repair pathways are required to permit resumption of replication. Collapsed replication 
forks are recognised by the checkpoint machinery, which will in turn trigger cell cycle 
arrest 12, DNA repair 31 or cell death through apoptosis or senescence 32-34. Although we 
know very little of the nature of replication lesions, there is an increasing body of 
information concerning pathways that repair them. Homologous recombination plays a 
central role in the repair of most replication lesions formed by anti-cancer drugs 5,6,15,35. 
There are several ways by which homologous recombination is utilised to restart 
replication. The sequence identity between two newly synthesised DNA molecules can be 
used to restart replication behind the replication block. Also, recombination can be used 
to bypass DNA lesions, in a process called template switching (see 36 for details). Other 
repair pathways active at replication forks involve the Fanconi anaemia associated 
repair 37, endonuclease-mediated repair, such as mediated by the Mus81 endonuclease38, 
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and RecQ-mediated repair, involving DNA helicases such as BLM 39, WRN 40,41 and 
other members of the RecQ family of helicases 42. Several of the proteins in these 
pathways have been found to be directly linked with homologous recombination 43 or the 
resolution of recombination products such as Holliday junctions 39,41,44,45. However, cells 
that are defective in these pathways show distinct differences from recombination 
defective cells, indicating that they represent different but overlapping repair pathways 46. 
Cells defective in a specific DNA repair pathway exhibit sensitivity to drugs 
producing DNA lesions that are normally repaired by this pathway. This sensitivity has 
been exploited to isolate hamster cell lines showing hypersensitivity to anti-cancer drugs 
(e.g. etoposide, mitomycin C) and ionizing radiation, and also to allow cloning of genes 
involved in DNA repair 47. The DNA repair pathways involved in the repair of damage 
caused by various anti-cancer agents are summarised in Figure 1. These DNA repair 
pathways are often up-regulated in tumour cells, resulting in resistance to 
chemotherapeutic drugs 48. Importantly, these DNA repair pathways can be inhibited 
pharmacologically to potentially increase the efficacy or specificity of anti-cancer agents 
(see below).  
 
Current DNA repair inhibitors for cancer treatment  
The basic understanding of DNA repair mechanisms, from the principles of the DNA 
lesions created and the pathways required to repair these lesions, has greatly increased 
during the past years. This permits a rational combination of cytotoxic agents and 
inhibitors of DNA repair to enhance tumour killing. Specific inhibitors of DNA repair 
that have been developed as clinical agents are discussed in this section (see Figure 2). 
 
Sensitisers to alkylating agents. Despite the adverse side effects caused by alkylating 
agents on bone marrow and other normal tissues, drugs such as cyclophosphamide, 
ifosfamide, chlorambucil, melphalan and dacarbazine remain some of the most 
commonly prescribed chemotherapies in adults and children with various solid and 
haematological malignancies, particularly in multi-agent regimes combined with 
anthracyclines and steroids.  More recently, a DNA alkylator and methylator developed 
in the 1980s, temozolomide (an oral prodrug which crosses the blood brain barrier) has 
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changed clinical practice in the treatment of high grade gliomas in adults and children 
49,50.  The combination of PARP1 inhibition and temozolomide is currently in several 
clinical trials (see Figure 2). The rationale for this treatment strategy is that inhibition of 
PARP retards the repair of an intermediate damage lesion, the apurinic site, induced by 
temozolomide. However, this intermediate is not generally regarded as a major 
contributor to the cytotoxicity induced by temozolomide in the absence of PARP 
inhibition, as they are promptly removed by base excision repair in cells with abundant 
functional PARP1.  The success of the treatment rationale adopted by current clinical 
trials of GPI-21016 (Guilford Pharmaceuticals, Baltimore, MD), INO-1001 (Inotek 
Pharmaceuticals, Beverly, MA) and AG014699 (Pfizer GRD, La Jolla, CA) therefore 
depends on the overall biological role of and necessity for PARP in cancer cells trying to 
repair this type of damage.   
Another class of agents currently being tested in clinical trials in combination 
with temozolomide therapy consists of the pseudosubstrates for MGMT.  The lead 
compounds in this class have been O(6)-benzylguanine and lomeguatrib (AstraZeneca, 
Lund, Sweden), the latter also known as O(6)-(4-bromothenyl)guanine or PaTrin-2.  
Resistance to O(6-)alkylating agents can be overcome in preclinical models by depletion 
of MGMT 51 and a relationship exists between MGMT activity and resistance to 
chloroethylating nitrosoureas and methylating agents in tumour cells grown in vitro and 
in xenograft models (reviewed in 52).  O(6)-benzylguanine and lomeguatrib have recently 
been tested in phase I-II clinical trials and biologically effective doses have been 
established for both agents 53. However, results obtained so far indicate that, when used 
in combination with cytotoxic chemotherapy, myelosuppression is significantly 
enhanced, necessitating significant reductions in the doses of alkylating agents prescribed 
from those used in standard chemotherapy. On account of this lack of selectivity for 
malignant tissue versus normal bone marrow, no improvement in the therapeutic index 
has so far been demonstrated in clinical trials of these agents.     
 
Platinum chemotherapies. Cisplatin, carboplatin and oxaliplatin have become three of 
the most commonly prescribed chemotherapeutic drugs used to treat solid cancers in 
patients 54.  Platinum resistance, either intrinsic or acquired during cyclical treatment, is a 
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major clinical problem since additional agents that can be added to therapy in order to 
circumvent tumour resistance do not currently exist.    
Currently, platinum chemotherapy is being tested with PARP inhibition in 2 
clinical trials (Figure 2). The rationale for combining PARP inhibition with platinum 
chemotherapy is based on preclinical observations that PARP inhibitors preferentially kill 
neoplastic cells and induce complete or partial regression of a wide variety of human 
tumor xenografts in nude mice treated with platinum chemotherapy  55-57.  For example, 
ABT-888 (Abbott Laboratories, Chicago, IL), a potent inhibitor of PARP-1 and PARP-2, 
has been shown to potentiate regression of established tumours induced by 
temozolomide, cisplatin, carboplatin, or cyclophosphamide therapy in rodent orthotopic 
and xenograft models 58.  In monotherapy, ABT-888 exhibits no significant anticancer 
activity in these preclinical models. 
 DNA demethylating agents such as 2′-deoxy-5-azacytidine (decitabine; MGI 
Pharma, Bloomington, MN) have been combined with cisplatin or carboplatin to reverse 
drug resistance caused by hypermethylation silencing of mismatch repair genes. The 
toxicity of agents such as cisplatin depends at least partly on functional mismatch repair 
(Figure 2).  Preclinical data from xenograft models and translational studies from drug-
resistant cells and tissues that are mismatch repair deficient owing to MLH1 
hypermethylation have demonstrated increased chemotherapeutic efficacy when a 
demethylating agent is combined with platinum chemotherapy 59,60.  Decitabine is 
currently being tested in combination with carboplatin in a phase II clinical trial in 
patients with ovarian cancer.  
Attenuators of checkpoint signalling. An alternative approach to modulate DNA repair 
activity and potentially improving therapeutic index is to interfere with cell cycle 
checkpoint signalling.  XL844 (EXEL-9844) is a small-molecule inhibitor of the 
checkpoint kinases 1 and 2 (Chk1 and Chk2).  It causes inhibition of cell cycle arrest, 
progressive DNA damage, inhibition of DNA repair, and, ultimately, tumour cell 
apoptosis in cancer cells grown in vitro 61.  XL844 is currently being tested in a clinical 
trial in combination with the deoxycytidine analogue, gemcitabine, which normally 
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causes cell cycle arrest and apoptosis by incorporation into DNA. The treatment efficacy 
of the inhibitor of ATM kinase, KU55933 (AstraZeneca, Lund, Sweden), is currently in 
late preclinical development.   
Radiosensitisers. DNA-dependent protein kinase (DNA-PK) is highly important for DSB 
repair by non-homologous end joining/NHEJ following ionizing radiation, and cells 
defective in DNA-PK are highly sensitive to ionizing radiation 62.  Wortmannin is a 
fungal product that irreversibly inhibits PI-3 protein kinases, such as DNA-PK, at low 
nanomolar concentrations, resulting in antiproliferative effects and radiosensitisation in 
preclinical models 63.  Unfortunately, it has been found to be unsuitable for clinical 
applications due to its inherent toxicity and instability in cells 64.  Other small molecule 
inhibitors of DNA-PK have been synthesised which reversibly inhibit the kinase activity 
at low micromolar concentrations, and these are currently in transition from late 
preclinical development to early clinical trials.  In particular, NU7441 (AstraZeneca, 
Lund, Sweden), has demonstrated chemosensitization of topoisomerase II poisons and 
radiosensitization in a manner consistent with DNA-PKcs inhibition 65.   
 
 
DNA repair inhibitors as single agent treatment for DNA repair defective cancer  
As discussed above, most of the current small molecule inhibitors of DNA repair 
have so far been tested in early clinical trials as sensitisers of tumour cells to 
chemotherapy. However, DNA damage also occurs spontaneously in cells in the absence 
of treatments and DNA repair pathways are therefore essential for the survival of 
untreated cells. As many cancers are defective in DNA damage response and repair 
pathways (Table 1), synthetic lethal interactions can be utilised to advocate DNA repair 
inhibitors as monotherapy (Figure 3). DNA repair is an ideal target for inhibition in 
cancer cells, as the inhibitors should be exclusively toxic to cancer cells and therefore be 
associated with minimal side effects for patients (see BOX1 for a summary of advantages 
and limitations with DNA repair inhibitors as single treatment).  
Indeed, DNA repair inhibitors have been demonstrated to work as single agents to 
treat cancer, particularly in DNA repair defective tumours. The most notable example so 
far is a novel treatment for inherited breast and ovarian cancers that arise from cells 
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which have lost the wild-type copy of the BRCA1 or BRCA2 genes 66,67.  BRCA1- and 
BRCA2-mutated cells are defective in homologous recombination repair 68,69 and show 
extensive replication-associated lesions 70,71. These recombination defective cells are 100-
1000 fold more sensitive to PARP inhibitors used as monotherapy than are the 
heterozygote or the wild-type cell lines, indicating the potential to be exploited to 
specifically treat BRCA1 or BRCA2 defective tumours 66,67. The molecular explanation 
for this extreme sensitivity is the overlapping roles of DNA single strand break (SSB) 
repair, which is dependent on PARP1 72, and homologous recombination in repair at 
replication forks 67,73,74. Translation of this hypothesis has led to phase II clinical trials of 
monotherapy using the PARP inhibitor, AZD2281 (AstraZeneca, Lund, Sweden), 
currently recruiting patients with breast and ovarian cancer who harbour mutations in 
BRCA1 or BRCA2 genes. A separate phase II trial with the PARP-1 inhibitor AG014699 
(Pfizer GRD, La Jolla, CA) is due to open to recruitment in the near future in known 
carriers of BRCA1 or BRCA2 mutations with locally advanced or metastatic breast or 
ovarian cancers. 
Another synthetic lethal interaction has recently been discovered between the 
Fanconi anaemia repair pathway and the ATM checkpoint kinase 75 by the demonstration 
that two pancreatic tumour lines defective in the Fanconi anaemia pathway were more 
sensitive to the ATM inhibitor, KU-55933, than isogenic control lines.  This finding 
provides a rationale to explore ATM inhibitors in the treatment of Fanconi anaemia 
repair-defective pancreatic cancer.  
Mutations in DNA damage response and repair pathways are commonly 
associated with cancer (Table 1). Thus, it should be straightforward to exploit DNA 
repair inhibitors for the treatment of tumours carrying specific defects in DNA repair or 
damage signalling. We have compiled a list of reported cancer mutations in DNA repair 
genes and present synthetic lethal interactions demonstrated in S. cereviseae (Table I). 
Proteins encoded by the synthetic lethal-interacting genes may represent good targets for 
specific treatment of cancers carrying a mutation in DNA repair genes.  
Reliable biomarkers are critical for selection of patients that will respond to 
treatments in clinical trials. This is particularly important for treatments with DNA repair 
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inhibitors that exploit specific cancer defects for treatments, as cancers in patients 
without the DNA repair or damage response defect will not respond to treatment. Thus, 
the lack of reliable assays to measure biomarkers in accessible malignant tissues is an 
important barrier to the success of DNA repair inhibitors in the clinic. The most reliable 
markers are likely to be those that identify loss of specific post-translational 
modifications present in the DNA damage response and repair pathways, or upregulation 
of the activity of the targeted pathway (Figure 3).  
 
Exploiting tumour specific replication stress for targeted cancer treatment  
Current chemotherapy clearly proves that production of excessive replication lesions 
represents a highly successful means of killing cancer cells. It has been observed that 
tumour cells themselves exhibit a high level of endogenous replication lesions that result 
in genetic instability 33,76. Ideally, DNA repair inhibitors could be used to impair the 
repair of replication lesions present in tumour cells and covert them into fatal replication 
lesions that specifically kill cancer cells.  
 
Oncogene-induced replication stress. The transformation of normal cells to a cancerous 
state is often initiated by the activation of oncogenes, which provide excessive growth 
signals 77. Oncogene-induced growth signals often mimic the growth signals that are used 
by the body to transfer cells from quiescent into proliferative states. Early on during 
neoplastic transformation, the pre-cancerous cells are often recognised by checkpoint 
proteins (e.g. p53, Chk2), which stop cell proliferation by initiating apoptosis or 
senescence 78,79, cell inactivating processes termed the tumour barrier 80 It was recently 
shown that oncogene activation induces replication-associated DNA lesions, and that 
these lesions are responsible for triggering the cell cycle checkpoint response that 
activates the tumour barrier33,34,81,82 (Figure 4).  
 Genes encoding proteins in the checkpoint pathways (e.g. the p53 pathway) are 
often mutated during cancer development 83, allowing cells to evade the tumour barrier 
and continue to proliferate (Figure 4). A key feature of cancer cells which express 
oncogenes and have managed to evade the tumour barrier, is that they have a higher level 
of endogenous replication-associated lesions than normal cells.  This in turn contributes 
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to genetic instability 84 that will assist the tumour to induce the genetic changes required 
for continued transformation to malignancy 76. More importantly, the replication lesions 
caused by oncogene activation resemble those produced by anti-cancer treatments 33 
which need to be repaired for the cancer cells to survive. We therefore suggest that future 
DNA repair inhibitors should be used to make existing cancer-specific replication lesions 
more toxic, resulting in fatal replication lesions selectively killing oncogene-expressing 
cancer cells. 
 
Hypoxia-associated replication stress. More advanced cancers are exposed to another 
source of replication stress, owing to the tumour microenvironment. Tumours are often 
hypoxic, which have been shown to disrupt DNA synthesis 85. These conditions cause 
replication lesions that activate the ATM/ATR mediated checkpoint response 86-88. 
Furthermore, DNA repair is down-regulated in hypoxic cells 89, which cumulatively 
contributes to the genetic instability observed in these cells 90,91. In this case, inhibitors of 
the checkpoint response might be more efficient than inhibitors of DNA repair 92.  
In summary, cancer cells are potentially exposed to unusually high levels of 
replication stress and endogenous DNA damage during cancer development. A future 
challenge will be to characterise forms of replication lesions occurring during different 
stages of carcinogenesis, which may be exploited for therapy. 
 
Conclusions 
 
The potential of DNA repair inhibitors in future cancer therapy is starting to be realised. 
Although selective inhibition of DNA repair pathways can be used to enhance current 
chemotherapy and radiotherapy, the most attractive use of DNA repair inhibitors may be 
in utilising cancer defects for more selective cell killing. DNA repair inhibitors that 
exploit tumour mutations in DNA repair pathways to convert spontaneous DNA lesions 
into fatal replication lesions may represent the most straightforward means to find 
selective treatments. This type of therapy is highly advantageous when compared to 
current chemotherapy as it is likely to produce minimal side effects whilst resulting in 
highly toxic replication lesions that will actively trigger cell death in cancer cells. A 
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potential limitation of this approach is that it is likely confined to DNA repair-defective 
tumours and that resistance mechanisms may develop. A more challenging treatment 
strategy is the inhibition of the repair of tumour-specific replication lesions and 
conversion of these into fatal lesions. Replication stress appears to be present in a 
majority of tumours, during at least one stage of carcinogenesis. Thus, the conversion of 
replication stress into fatal replication lesions could potentially be used to target a wide 
range of tumours. As we are still unaware of the exact nature of the replication lesions 
formed by many traditional chemotherapies, there is still considerable work to be done in 
characterising tumour-specific lesions to target cancers. Basic research into 
understanding the nature of toxic replication lesions as well as obtaining a more complete 
picture of all DNA repair pathways and their interplay is critical for the future of DNA 
repair inhibitors as single agents in cancer therapy.     
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BOX 1. Advantages and limitations using DNA repair inhibitors as single agents in 
treatment of cancers: 
(1) DNA repair inhibitors can exploit tumour-specific defects in checkpoint 
signalling and DNA repair to convert endogenous DNA lesions into fatal replication 
lesions that selectively kill tumour cells.  
(2) A general problem for novel cancer therapies is that they are not sufficiently 
efficient to replace current therapy. As a result many enzyme inhibitors, that are not 
targeting DNA repair, have failed at the phase III or IV stage during clinical trials owing 
to a general lack of efficacy. Inhibition of DNA repair amplifies toxic replication-
associated DNA lesions that directly result in cell death. DNA repair inhibitors should 
therefore be highly efficient at killing tumours.   
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(3) Extensive cross-talk between DNA repair pathways minimizes side effects in 
normal cells during inhibition of a single DNA repair pathway.  
(4) Tumour inactivation of DNA damage signalling and DNA repair are often 
relatively early events during carcinogenesis, suggesting that non-toxic DNA repair 
inhibitors may be considered in the treatment of patients with pre-malignant or early  
neoplastic lesions (e.g. ductal carcinoma-in-situ in patients with BRCA1 and BRCA2 
inherited breast and ovarian cancer; intestinal lesions in patients with hMLH1 and 
hMSH2 hereditary non-polyposis colorectal cancer).  
(5) Extensive crosstalk between DNA repair pathways likely results in acquisition of 
resistance mechanisms in tumours, which is a limitation for killing late stage tumours.  
 
 
 
 
Figure 1. Overview of DNA repair pathways involved in repairing toxic DNA 
lesions formed by cancer treatments. DNA damaging agents used in 
cancer treatment induce a diverse spectrum of toxic DNA lesions. These 
lesions are recognised by a variety of DNA repair pathways which are 
lesion-specific but highly overlapping. (A) Ionising radiation and 
radiomimetic drugs are the only agents to directly induce double strand 
breaks (DSBs), which are toxic independently of replication, and 
predominantly repaired by non-homologous end joining. (B) Mono-and (C) 
bi- functional alkylators induce DNA base modifications, which interfere 
with DNA synthesis and are processed into toxic lesions in a mismatch 
repair dependent manner. The base and nucleotide excision repair 
pathways are, together with alkyltransferases, major repair pathways, 
whereas other repair pathways repair toxic replication lesions, such as 
those produced following interstrand crosslinks.  (D) Anti-metabolites 
interfere with nucleotide metabolism and DNA synthesis, causing 
mismatch repair mediated, but poorly characterised replication lesions. 
The repair pathways involved in repair of anti-metabolite-induced lesions 
are, apart from base excision repair, poorly characterised.  (E) 
Topoisomerase inhibitors trap topoisomerase I or II in transient cleavage 
complexes with DNA, thus creating indirect DNA breaks and interfering 
with replication. (F) Replication inhibitors induce replication fork stalling 
and collapse, resulting in indirect DSBs. The relative contributions of the 
major repair pathways to the respective types of DNA damage outlined 
are indicated by the sizes of the boxes. Abbreviations used: AT, 
alkyltransferases; BER, base excision repair; O2G, DNA dioxygenases; 
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ENDO, endonuclease-mediated repair; FA, Fanconi anaemia-mediated 
repair; HR, homologous recombination; NER, nucleotide excision repair; 
NHEJ, non-homologous end joining; RecQ, RecQ-mediated repair; SSBR, 
DNA single-strand break repair; TLS, trans lesion synthesis. 
 
Figure 2. Ongoing clinical trials of small molecule inhibitors of the DNA 
damage response and related signalling pathways. The recent or 
current stage of development of clinical trials is indicated for individual 
compounds, which are grouped by molecular target. For details of specific 
agents, see main text.  
 
Figure 3. Synthetic lethal interactions to identify molecular targets and 
biomarkers for inhibitors of DNA repair.  Proteins that interact are often 
within functional modules involved in catalysing checkpoint and repair 
pathways. A mutation in a single tumour suppressor gene (A) normally 
impairs the full functional module. Such loss of a checkpoint or repair 
pathway results in genetic instability, which would lead to cell death unless 
a DNA repair salvage pathway (B) is upregulated. As the two pathways 
collaborate to maintain survival, targeting pathway B in monotherapy will 
specifically kill tumour cells and be non-toxic to normal cells, as they can 
use pathway A for survival. An additional mutation (C) upstream of the 
targeted pathway B causes complete resistance to the treatment. For 
instance, if pathways A+B are required for resolving a certain type of 
recombination intermediate, a mutation in a protein C involved in the 
formation of this recombination intermediate (e.g. BRCA2, which is 
involved in early stages of recombination) will make pathways A+B 
redundant. In the absence of C, the (D)+(E) pathways would be used to 
rescue replication, independently of recombination. A novel monotherapy 
targeting pathways D+E would then be needed to kill B resistant tumour 
cells. Proteins are indicated by circles, protein interactions with red lines, 
functional modules with blue boxes.  Black boxes indicate mutated 
pathways. Red boxes indicate salvage DNA repair pathways.  
 
 
Figure 4. Oncogene-induced replication stress as a target for DNA repair 
inhibitors.  Oncogene expression results in unscheduled replication origin 
firing, which decreases the distance between origins 34 and causes 
replication forks to collapse 33. Such replication lesions activate the tumour 
barrier, including the ATM-mediated checkpoint pathway, to trigger 
apoptosis or senescence and to prevent tumour outgrowth 81,82. 
Inactivation of checkpoint pathways (for instance by p53 mutation) results 
in cancer cells evading apoptosis and senescence, which allows 
continued proliferation. Collapsed replication forks need to be repaired to 
allow cell survival. Tumour defects in checkpoint and repair pathways will 
result in collapsed forks that are often incorrectly repaired, resulting in 
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genetic instability that will drive future mutations. Here, we suggest that 
tumour-specific replication lesions can be converted into fatal replication 
lesions through inhibition of DNA repair. Such therapy is likely to be 
tumour specific as normal cells should not have oncogene-induced 
replication stress.  
 
   
 
 
Definitions 
 
Alkylating agents 
Electrophilic compounds that are reactive either directly or following metabolism 
and bind covalently to electron rich atoms in DNA bases (i.e. oxygen and 
nitrogen).  
 
Alkyltransferases 
Class of enzymes that directly reverse DNA base modifications induced by 
alkylating agents by transferring the alkyl group from the base on to the protein.  
 
Antimetabolites 
Compounds with similar chemical structures to nucleotide metabolites that 
interfere with nucleotide biosynthesis or are incorporated into DNA.  
 
Base excision repair 
A repair pathway that replaces missing or modified DNA bases, such as those 
produced by alkylating agents or in spontaneously degraded DNA, with the 
correct DNA base.  
 
Biomarkers 
A molecule or substance whose detection indicates a particular disease state or 
treatment response.  
 
DNA-dioxygenases 
Class of enzymes that directly reverse DNA base methylations via an oxidation 
mechanism. The human DNA-dioxygenase ABH2 is believed to act at replication 
forks. 
 
Endonuclease-mediated repair  
A repair pathway that introduces a DNA single-strand break in a DNA structure to 
facilitate continuous repair.  
 
Fanconi anemia-associated repair 
A repair pathway with largely unknown function active at damaged replication 
forks. 
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Homologous recombination 
A process that can copy a DNA sequence from an intact DNA molecule (often 
the newly synthesised sister chromatid) to repair or bypass replication lesions.  
 
Hypoxia 
A shortage of oxygen. In cancer this is often the result of insufficient vasculature. 
 
Mismatch repair 
Acts during DNA replication to correct base-pairing errors made by the DNA 
polymerases.  
 
Non-homologous end joining 
Connects and re-seals the two ends of a DNA double strand break without the 
need for sequence homology between the ends. 
 
Nucleotide excision repair 
Removes large DNA adducts or base modifications which distort the double helix 
and use the opposite strand as template for repair.  
 
RecQ-mediated repair 
A repair pathway that unwinds complex DNA structure to facilitate repair.  
 
Synthetic lethality 
Genetic phenomenon where the combination of two non-lethal mutations results 
in lethality because the second mutation inactivates a backup mechanism 
allowing for tolerance of the first mutation and vice versa. 
 
Trans-lesion synthesis 
Mechanism during DNA replication where the standard DNA polymerase is 
temporarily exchanged for a specialised polymerase which can synthesise DNA 
across base damage on the template strand.  
 
Therapeutic index 
The therapeutic index describes the ability of a treatment strategy to kill cancer 
cells in preference to cells in normal tissues. 
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Table I. Synthetic lethal interations in DNA repair and cell cycle checkpoint genes 
implicated in cancer.  Abbreviations used: BER, base excision repair; FA, 
Fanconi anaemia-mediated repair; HR, homologous recombination; NER, 
nucleotide excision repair; NHEJ, non-homologous end joining; MMR, 
mismatch repair; RecQ, RecQ-mediated repair 
 
 
Path
way Protein Syndrome  Primary cancers 
Bioma
rker 
Synthetic 
lethality 
Homol
og 
 S. 
cerevi
siae Synthetic lethality  S. cerevisiae 93-172 
HR 
 BRCA1   breast, ovarian 173   PARP1 66 - - 
 BRCA2 
Fanconi's 
anemia breast, ovarian 174  PARP1 66,67 - - 
 RAD54B  
non-Hodgkin 
lymphoma, colon 
cancer 175   rdh54 
cla4, bim1, rad27, ctf4, ctf8, ctf18, dcc1, 
tof1, pol32, srs2, ulp1, elg1, nup133, 
nup120, ccr4, cik1, ctk1, ctk2, ctk3, 
lsm7, pop2, rnr4, rrm3, sod1, swi6, 
tsa1. 
 RAD51B  
lipoma, uterine 
leiomyoma 176   rad51 
rad27, ctf4, ctf8, ctf18, tof1, pol32, elg1, 
orc2, orc5, nup133, nup120, ctk1, ctk2, 
ctk3, rnr4, sod1, swi6, tsa1, ubc9 
 CtIP  
colorectal cancer 
177   sae2 sgs1, rad27, rrm3, dia2, pph3 
NHEJ 
 MRE11 
Ataxia-
telangiectasia- 
like disorder 
(ATLD) 
colorectal cancer 
178     mre11 
rad27, bim1, ctf4, ctf18, dcc1, top1, 
chs1, chs5, kre9, rm3, sap30, elg1, 
srs2, yku80, ulp1, xrs2, rad50, nup133, 
nup120, hsp82, orc6, cdc6, ccr4, dia2, 
ccs1, cik1, ctk1, ctk2, ctk3, mdm12, 
pop2, rnr4, sod1, swi6, tsa1, vid22, 
pph3, gcs1, dna2 
 LIG4 
LIG4 
syndrome Leukemia 179   lig4 - 
 Artemis 
Omenn 
syndrome Lymphoma 180   pso2 - 
MMR 
 hMSH2   
hereditary 
nonpolyposis 
colorectal cancer 
(HNPCC) 181 
micro 
satelit
e 
instabil
ity 
(MSI)  msh2 pol3 
 hMLH1  HNPCC 182 MSI  mlh1 cdc7, pol3, mms4 
 hMSH6  HNPCC 183 MSI  msh6 pol3 
 hPMS1  HNPCC 184 MSI  pms1 pol3 
 hPMS2  HNPCC 184 MSI  pms1 pol3 
 hMLH3  HNPCC 185 MSI  mlh3 none 
RecQ homologues 
 BLM 
Bloom's 
syndrome Various 186 
Elevat
ed 
SCE  sgs1 
srs2, dcc1, mrc1, cdc7, cdc8, hst3, 
dna2, est2, slx5, slx8, wss1, yku70, 
rnr202, elg1, ccs1, nup133, nup120, 
dia2, slx1, sae2, slx4, pol31, siz1, nfi1, 
asf1, rnr1, rrm3, mgs1, csm3, esc2, 
rtt107, top1, swe1, pub1, rpl24a, sis2, 
sod1, pby1, ctf18, ctf4, mms4, mus81, 
rad50 
 WRN 
Werner's 
syndrome Various 187   sgs1 
srs2, dcc1, mrc1, cdc7, cdc8, hst3, 
dna2, est2, slx5, slx8, wss1, yku70, 
rnr202, elg1, ccs1, nup133, nup120, 
dia2, slx1, sae2, slx4, pol31, siz1, nfi1, 
asf1, rnr1, rrm3, mgs1, csm3, esc2, 
rtt107, top1, swe1, pub1, rpl24a, sis2, 
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sod1, pby1, ctf18, ctf4, mms4, mus81, 
rad50 
 RECQL4 
Rothmund-
Thomson 
syndrome 
skin basal and 
sqamous cell, 
osteosarcoma 187   sgs1 
srs2, dcc1, mrc1, cdc7, cdc8, hst3, 
dna2, est2, slx5, slx8, wss1, yku70, 
rnr202, elg1, ccs1, nup133, nup120, 
dia2, slx1, sae2, slx4, pol31, siz1, nfi1, 
asf1, rnr1, rrm3, mgs1, csm3, esc2, 
rtt107, top1, swe1, pub1, rpl24a, sis2, 
sod1, pby1, ctf18, ctf4, mms4, mus81, 
rad50 
Damage signaling 
 ATM 
Ataxia-
telangiectasia  Leukemia 188   
PARP1 
189,190, 
FANC 75 tel1 mec1, dna2 
 NBS1 
Nijmegen 
breakage 
syndrome  Various 191   xrs2 
ctk2, ctk3, dia2, mdm12, nup133, pop2, 
rnr4, sod1, swi6, tsa1, vid22, rad27, 
cdc73, kar3, mrc1, pol32, cdc45, mms4, 
srs2, rrm3, mre11, elg1, nup120, orc6, 
cdc6, ccr4, ccs1, mms22, cik1, ctk1 
 p53 Li-Fraumeni Various 192   - - 
 CHEK2 Li-Fraumeni Various 193   
dun1/r
ad53 
chk1, bmh1, nat1, rad9, ubx7, bsc4, 
cdc7, mec1, pol3, clb5, rnr4, rmi1, elg1, 
orc6, cdc6, ccr4, cdc73, clb5, ctk3, 
eaf5, htz1, ies2, lsm1, mrc1, npl3, pep3, 
pep5, pop2, puf4, rad27, snf8, eaf1, 
vps34, yaf9, dia2, dbf4, pap2 
NER        
 XPA 
Xeroderma 
pigmentosum 
(XP) skin cancers 194     rad14 gmh1, ntg1, ntg2 
 XPB 
XP, Cockayne 
syndrome 
(CS) skin cancers 195   rad25 rad3, sti1 
 XPC XP skin cancers 196   rad4 
ric1, ypt6, csm3, hsp82,  ctf4, ctf18, 
dcc1, tof1, rad23, mad2 
 XPD 
XP, CS, 
Trichothiodyst
rophy skin cancers 197   rad3 
act1, nip7, nop1, rad50, rad52, kin28, 
ssl2 
 
XPE/ 
DDB2 XP 
basal cell 
carcinomas 198   -  
 XPF XP skin cancers 199   rad1 
ntg1, ntg2, apn2, apn2, rad27, tdp1, 
mec1 
 XPG XP 
squamous cell 
carcinoma, head 
and neck 200   rad2 none 
 XPV XP skin cancers 201   rad30 msh6, pms1 
 ERCC1 
cerebro-oculo-
facio-skeletal 
syndrome 
squamous cell 
carcinoma, head 
and neck 200    rad10 cla4, gim4, mec1, mad2, apn1, apn2 
Crosslink repair 
 FANCA 
Fanconi's 
anemia Various 202 
 FANC
D2 
Ubiquti
nation 
75 ATM 75 - 
- 
 FANCB 
Fanconi's 
anemia Various 202   - 
- 
 FANCC 
Fanconi's 
anemia Various 202 
FANC
D2 
Ubiquti
nation 
75 ATM 75 - 
- 
 FANCD2 
Fanconi's 
anemia Various 202  ATM 75 - 
- 
 FANCE 
Fanconi's 
anemia Various 202 
FANC
D2 
Ubiquti
nation 
75 ATM 75 - 
- 
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 FANCF 
Fanconi's 
anemia Various 202   - 
- 
 
FANCG/
XRCC9 
Fanconi's 
anemia Various 202 
FANC
D2 
Ubiquti
nation 
75 ATM 75 - 
 
- 
 FANCJ 
Fanconi's 
anemia Various 202   - 
- 
 FANCL 
Fanconi's 
anemia Various 202   - 
- 
BER 
 PolB   Various 203     pol4 - 
 FEN1  Various 204   rad27 
 lcd1, sgs1, mms4, mus81, sae2, rad50, 
srs2, ddc1, cac2, exo1, mre11, rad6, 
rad9, rad17, rad24, rad52, xrs2, ctf4, 
rpl27a, rps30b, doc1, esc2, hst1, hpc2, 
csm3, ccs1, sis2, sod1, ydj1, hst3, 
ylr352w, ypr116w, bud27, ctf18, dcc1, 
chl1, mrc1, tof1, pol32, cdc8, exo1, 
mre11, pol3, rad1, cln1, cln2, rad51, 
rad53, rad54, rad55, rad57, rad59, rfc1, 
xrs2, ulp1, elg1, rnh201, rnh202, 
rnh203, mec3, rad6, slx8, slx9, top3, 
asf1, rlf2, pap2, rpn4, doa4, bro1, grr1, 
nup84, nup120, nup133, nat3, sfp1, 
thp1, tef4, aat2, gas1, pep5, pmr1, 
ume6, bre1, slx5, ige1,  mec1, mec3, 
mms22, arp8, dia2, hur1, lrs4, lsm7, 
lte1, npl3, rmd9, rtf1, uaf30, eaf1, sae2, 
pph3, ulp1, nup60 
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